Search

Your search keyword '"Kim Won Seog"' showing total 2,418 results
Start Over Author "Kim Won Seog"
2,418 results on '"Kim Won Seog"'

6. ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study

Author

Maris, Michael, Salles, Gilles, Kim, Won Seog, Kim, Tae Min, Lyons, Roger M., Arellano, Martha, Karmali, Reem, Schiller, Gary, Cull, Elizabeth, Abboud, Camille N., Batlevi, Connie, Kagiampakis, Ioannis, Rebelatto, Marlon C., Lee, Young, Kirby, Lyndon C., Wang, Fujun, Bothos, John, Townsley, Danielle M., Fathi, Amir T., and Ribrag, Vincent

Published
2024
Full Text
View/download PDF

7. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium

Author

Han, Jessy Xinyi, Koh, Min Jung, Boussi, Leora, Sorial, Mark, McCabe, Sean M., Peng, Luke, Singh, Shambhavi, Eche-Ugwu, Ijeoma Julie, Gabler, Judith, Fernandez Turizo, Maria J., MacVicar, Caroline T., Garg, Aditya, Disciullo, Alexander, Chopra, Kusha, Lenart, Alexandra, Nwodo, Emmanuel, Barnes, Jeffrey, Koh, Min Ji, Miranda, Eliana, Chiattone, Carlos, Stuver, Robert, Horwitz, Steven M., Merrill, Mwanasha, Jacobsen, Eric, Manni, Martina, Civallero, Monica, Skrypets, Tetiana, Lymboussaki, Athina, Federico, Massimo, Kim, Yuri, Kim, Jin Seok, Cho, Jae Yong, Eipe, Thomas, Shet, Tanuja, Sridhar, Epari, Shetty, Alok, Saha, Saswata, Jain, Hasmukh, Sengar, Manju, Van Der Weyden, Carrie, Prince, Henry Miles, Hamouche, Ramzi, Murdashvili, Tinatin, Foss, Francine, Gentilini, Marianna, Casadei, Beatrice, Zinzani, Pier Luigi, Okatani, Takeshi, Yoshida, Noriaki, Yoon, Sang Eun, Kim, Won-Seog, Panchoo, Girisha, Mohamed, Zainab, Verburgh, Estelle, Alturas, Jackielyn Cuenca, Al-Mansour, Mubarak, Ford, Josie, Cabrera, Maria Elena, Ku, Amy, Bhagat, Govind, Ma, Helen, Sawas, Ahmed, Kariya, Khyati Maulik, Iwasaki, Makoto, Bhanushali, Forum, O’Connor, Owen A., Marchi, Enrica, Shen, Changyu, Shah, Devavrat, and Jain, Salvia

Published
2025
Full Text
View/download PDF

9. CHRONOS-4: phase 3 study of copanlisib plus rituximab-based immunochemotherapy in relapsed indolent B-cell lymphoma

Author

Zinzani, Pier Luigi, Wang, Huaqing, Feng, Jifeng, Kim, Tae Min, Tao, Rong, Zhang, Huilai, Fogliatto, Laura, Maluquer Artigal, Clara, Özcan, Muhit, Yanez, Eduardo, Kim, Won Seog, Kirtbaya, Dmitry, Kriachok, Iryna, Maciel, Felipe, Xue, Hongwei, Bouabdallah, Krimo, Phelps, Charles, Chaturvedi, Shalini, Weispfenning, Anke, Morcos, Peter N., Odongo, Fatuma, Buvaylo, Viktoriya, Childs, Barrett H., Dreyling, Martin, Matasar, Matthew, and Ghione, Paola

Published
2024
Full Text
View/download PDF

10. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma

Author

Witzig, Thomas, Sokol, Lubomir, Kim, Won Seog, de la Cruz Vicente, Fátima, Martín García-Sancho, Alejandro, Advani, Ranjana, Roncero Vidal, Jose Maria, de Oña Navarrete, Raquel, Marín-Niebla, Ana, Rodriguez Izquierdo, Antonia, Terol, María José, Domingo-Domenech, Eva, Saunders, Andrew, Bendris, Nawal, Mackey, Julie, Leoni, Mollie, and Foss, Francine

Published
2024
Full Text
View/download PDF

14. Allogeneic hematopoietic stem cell transplantation for NK/T-cell lymphoma: an international collaborative analysis

Author

Berning, Philipp, Schmitz, Norbert, Ngoya, Maud, Finel, Hervé, Boumendil, Ariane, Wang, Fengrong, Huang, Xiao-Jun, Hermine, Olivier, Philippe, Laure, Couronné, Lucile, Jaccard, Arnaud, Liu, Daihong, Wu, Depei, Reinhardt, Hans Christian, Chalandon, Yves, Wagner-Drouet, Eva, Kwon, Mi, Zhang, Xi, Carpenter, Ben, Yakoub-Agha, Ibrahim, Wulf, Gerald, López-Jiménez, Javier, Sanz, Jaime, Labussière-Wallet, Hélène, Shimoni, Avichai, Dreger, Peter, Sureda, Anna, Kim, Won Seog, and Glass, Bertram

Published
2023
Full Text
View/download PDF

16. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Author

Song, Yuqin, Malpica, Luis, Cai, Qingqing, Zhao, Weili, Zhou, Keshu, Wu, Jianqiu, Zhang, Huilai, Mehta-Shah, Neha, Ding, Kaiyang, Liu, Yao, Li, Zengjun, Zhang, Liling, Zheng, Meifang, Jin, Jie, Yang, Haiyan, Shuang, Yuerong, Yoon, Dok Hyun, Gao, Sujun, Li, Wenyu, Zhai, Zhimin, Zou, Liqun, Xi, Yaming, Koh, Youngil, Li, Fei, Prince, Miles, Zhou, Hui, Lin, Lie, Liu, Hui, Allen, Pamela, Roncolato, Fernando, Yang, Zhenfan, Kim, Won-Seog, and Zhu, Jun

Published
2024
Full Text
View/download PDF

17. Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy

Author

Jeong Seong Hyun, Eom Hyeon Seok, Lee Hye Won, Kim Won Seog, Kim Seok Jin, Jung Hyun Ae, Kim Soo Jeong, Kim Jin Seok, Kim Yu Ri, Park Joon Seong, Cheong June-Won, and Min Yoo Hong

Subjects
peripheral T-cell lymphoma, not otherwise specified, lymphopenia, international prognostic index, prognostic factor, Diseases of the blood and blood-forming organs, RC633-647.5, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

Published
2011
Full Text
View/download PDF

19. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Author

Hapgood, Greg, Civallero, Monica, Stepanishyna, Yana, Vose, Julie, Cabrera, Monica Elena, Advani, Ranjana H., Pileri, Stefano A., Manni, Martina, Horwitz, Steven M., Foss, Francine M., Hitz, Felicitas, Radford, John, Dlouhy, Ivan, Chiattone, Carlos, Kim, Won Seog, Skrypets, Tetiana, Nagler, Arnon, Trotman, Judith, Luminari, Stefano, and Federico, Massimo

Published
2023
Full Text
View/download PDF

22. Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Author

Song, Yuqin, Tilly, Hervé, Rai, Shinya, Zhang, Huilai, Jin, Jie, Goto, Hideki, Terui, Yasuhito, Shin, Ho-Jin, Kim, Won Seog, Cao, Junning, Feng, Jifeng, Eom, Hyeon Seok, Kim, Tae Min, Tsai, Xavier Cheng-Hong, Gau, Jyh-Pyng, Koh, Hideo, Zhang, Liling, Song, Yongping, Yang, Yu, Li, Wei, Huang, He, Ando, Kiyoshi, Sharman, Jeff P., Sehn, Laurie H., Bu, Lilian, Wang, Xin, Jiang, Yanwen, Hirata, Jamie, Lee, Calvin, Zhu, Jun, and Izutsu, Koji

Published
2023
Full Text
View/download PDF

26. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Author

Campo, Elias, Jaffe, Elaine S., Cook, James R., Quintanilla-Martinez, Leticia, Swerdlow, Steven H., Anderson, Kenneth C., Brousset, Pierre, Cerroni, Lorenzo, de Leval, Laurence, Dirnhofer, Stefan, Dogan, Ahmet, Feldman, Andrew L., Fend, Falko, Friedberg, Jonathan W., Gaulard, Philippe, Ghia, Paolo, Horwitz, Steven M., King, Rebecca L., Salles, Gilles, San-Miguel, Jesus, Seymour, John F., Treon, Steven P., Vose, Julie M., Zucca, Emanuele, Advani, Ranjana, Ansell, Stephen, Au, Wing-Yan, Barrionuevo, Carlos, Bergsagel, Leif, Chan, Wing C., Cohen, Jeffrey I., d'Amore, Francesco, Davies, Andrew, Falini, Brunangelo, Ghobrial, Irene M., Goodlad, John R., Gribben, John G., Hsi, Eric D., Kahl, Brad S., Kim, Won-Seog, Kumar, Shaji, LaCasce, Ann S., Laurent, Camille, Lenz, Georg, Leonard, John P., Link, Michael P., Lopez-Guillermo, Armando, Mateos, Maria Victoria, Macintyre, Elizabeth, Melnick, Ari M., Morschhauser, Franck, Nakamura, Shigeo, Narbaitz, Marina, Pavlovsky, Astrid, Pileri, Stefano A., Piris, Miguel, Pro, Barbara, Rajkumar, Vincent, Rosen, Steven T., Sander, Birgitta, Sehn, Laurie, Shipp, Margaret A., Smith, Sonali M., Staudt, Louis M., Thieblemont, Catherine, Tousseyn, Thomas, Wilson, Wyndham H., Yoshino, Tadashi, Zinzani, Pier-Luigi, Dreyling, Martin, Scott, David W., Winter, Jane N., and Zelenetz, Andrew D.

Published
2022
Full Text
View/download PDF

28. Assessing the Efficacy of Bortezomib and Dexamethasone for Induction and Maintenance Therapy in Relapsed/Refractory Cutaneous T-Cell Lymphoma: A Phase II CISL1701/BIC Study.

Author

Choi, Yoon Seok, Shim, Joonho, Kang, Ka-Won, Yoon, Sang Eun, Hong, Jun Sik, Lim, Sung Nam, Yhim, Ho-Young, Kwon, Jung Hye, Lee, Gyeong-Won, Yang, Deok-Hwan, Oh, Sung Yong, Shin, Ho-Jin, Eom, Hyeon-Seok, Yoon, Dok Hyun, Lee, Hong Ghi, Jeong, Seong Hyun, Kim, Won Seog, and Kim, Seok Jin

Subjects
CUTANEOUS T-cell lymphoma, PROGNOSIS, PROGRESSION-free survival, PERIPHERAL neuropathy, TREATMENT effectiveness
Abstract

Purpose: This multicenter, open-label, phase II trial evaluated the efficacy and safety of bortezomib combined with dexamethasone for the treatment of relapsed/refractory cutaneous T-cell lymphoma (CTCL) in previously treated patients across 14 institutions in South Korea. Materials and Methods: Between September 2017 and July 2020, 29 patients with histologically confirmed CTCL received treatment, consisting of eight 4-week cycles of induction therapy followed by maintenance therapy, contingent upon response, for up to one year. The primary endpoint was the proportion of patients achieving an objective global response. Results: Thirteen of the 29 patients (44.8%) achieved an objective global response, including two complete responses. The median progression-free survival (PFS) was 5.8 months, with responders showing a median PFS of 14.0 months. Treatment-emergent adverse events were generally mild, with a low incidence of peripheral neuropathy and hematologic toxicities. Despite the trend toward shorter PFS in patients with higher mutation burdens, genomic profiling before and after treatment showed no significant emergence of new mutations indicative of disease progression. Conclusion: This study supports the use of bortezomib and dexamethasone as a viable and safe treatment option for previously treated CTCL, demonstrating substantial efficacy and manageability in adverse effects. Further research with a larger cohort is suggested to validate these findings and explore the prognostic value of mutation profiles. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

31. Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study

Author

Kwak, Larry W., Sancho, Juan-Manuel, Cho, Seok-Goo, Nakazawa, Hideyuki, Suzumiya, Junji, Tumyan, Gayane, Kim, Jin Seok, Menne, Tobias, Mariz, José, Ilyin, Nikolai, Jurczak, Wojciech, Lopez Martinez, Aurelio, Samoilova, Olga, Zhavrid, Edvard, Yañez Ruiz, Eduardo, Trneny, Marek, Popplewell, Leslie, Ogura, Michinori, Kim, Won-Seog, Lee, Sang Joon, Kim, Sung Hyun, Ahn, Keum Young, and Buske, Christian

Published
2022
Full Text
View/download PDF

33. Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.

Author

Kim, Jeong A, primary, Hahn, Uwe, additional, Kim, Won-Seog, additional, Fleury, Isabelle, additional, Laribi, Kamel, additional, Bergua Burgues, Juan Miguel, additional, Bouabdallah, Krimo, additional, Forward, Nick, additional, Bijou, Fontanet, additional, MacDonald, David, additional, Portell, Craig Anthony, additional, Ghesquieres, Hervé, additional, Nowakowski, Grzegorz S., additional, Yasenchak, Christopher A., additional, Rustia, Evelyn, additional, Fanale, Michelle, additional, Jie, Fei, additional, and Bartlett, Nancy L., additional

Published
2024
Full Text
View/download PDF

34. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results

Author

Rai, Shinya, primary, Kim, Won Seog, additional, Ando, Kiyoshi, additional, Choi, Ilseung, additional, Izutsu, Koji, additional, Tsukamoto, Norifumi, additional, Maruyama, Dai, additional, Tsukasaki, Kunihiro, additional, Kuroda, Junya, additional, Ando, Jun, additional, Hidaka, Michihiro, additional, Koh, Youngil, additional, Kato, Hisashi, additional, Uchida, Toshiki, additional, Yang, Deok Hwan, additional, Ishitsuka, Kenji, additional, Ishizawa, Kenichi, additional, Kim, Jin Seok, additional, Lee, Hong Ghi, additional, Minami, Hironobu, additional, Eom, Hyeon Seok, additional, Kurosawa, Mitsutoshi, additional, Lee, Jae Hoon, additional, Lee, Jong Seok, additional, Lee, Won Sik, additional, Nagai, Hirokazu, additional, Shindo, Takero, additional, Yoon, Dok Hyun, additional, Yoshida, Shinichiro, additional, Gillings, Mireille, additional, Onogi, Hiroshi, additional, and Tobinai, Kensei, additional

Published
2024
Full Text
View/download PDF

35. Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).

Author

Karimi, Yasmin, primary, Thieblemont, Catherine, additional, Ghesquieres, Hervé, additional, Cheah, Chan Y, additional, Clausen, Michael Roost, additional, Cunningham, David, additional, Jurczak, Wojciech, additional, Linton, Kim M., additional, Hutchings, Martin, additional, Phillips, Tycel Jovelle, additional, Farooq, Umar, additional, Kim, Won Seog, additional, Dinh, Minh H, additional, Ghosh, Jagannath, additional, Pallai, Rajash, additional, Wielgos-Bonvallet, Monica, additional, Eskelund, Christian, additional, Lugtenburg, Pieternella, additional, and Vose, Julie, additional

Published
2024
Full Text
View/download PDF

37. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Author

Lakhani, Nehal J, Chow, Laura Q M, Gainor, Justin F, LoRusso, Patricia, Lee, Keun-Wook, Chung, Hyun Cheol, Lee, Jeeyun, Bang, Yung-Jue, Hodi, Frank Stephen, Kim, Won Seog, Santana-Davila, Rafael, Fanning, Philip, Squifflet, Pierre, Jin, Feng, Kuo, Tracy C, Wan, Hong I, Pons, Jaume, Randolph, Sophia S, and Messersmith, Wells A

Published
2021
Full Text
View/download PDF

39. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project

Author

Advani, Ranjana H., Skrypets, Tetiana, Civallero, Monica, Spinner, Michael A., Manni, Martina, Kim, Won Seog, Shustov, Andrei R., Horwitz, Steven M., Hitz, Felicitas, Cabrera, Maria Elena, Dlouhy, Ivan, Vassallo, José, Pileri, Stefano A., Inghirami, Giorgio, Montoto, Silvia, Vitolo, Umberto, Radford, John, Vose, Julie M., and Federico, Massimo

Published
2021
Full Text
View/download PDF

42. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Author

Straus, David J, Długosz-Danecka, Monika, Connors, Joseph M, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Lee, Hun Ju, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M, Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle, and Radford, John

Published
2021
Full Text
View/download PDF

43. Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Author

Kim, Won Seog, Oki, Yasuhiro, Kim, Seok Jin, Yoon, Sang Eun, Ardeshna, Kirit M., Lin, Yi, Ruan, Jia, Porcu, Pierluigi, Brammer, Jonathan E., Jacobsen, Eric D., Yoon, Dok Hyun, Suh, Cheolwon, Suarez, Felipe, Radford, John, Budde, Lihua E., Kim, Jin Seok, Bachy, Emmanuel, Lee, Hun Ju, Bollard, Catherine M., Jaccard, Arnaud, Kang, Hye Jin, Inman, Shannon, Murray, Maryann, Combs, Katherin E., Lee, Daniel Y., Advani, Ranjana, Gunter, Kurt C., Rooney, Cliona M., and Heslop, Helen E.

Published
2021
Full Text
View/download PDF

44. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia

Author

Lee, Yong-Pyo, Yoon, Sang Eun, Song, Yuqin, Kim, Seok Jin, Yoon, Dok Hyun, Chen, Tsai-Yun, Koh, Young Il, Kang, Ka Won, Lee, Ho sup, Wei, Kevin Tay Kuang, Lim, Soon Thye, Poon, Michelle, Irawan, Cosphiadi, Zhao, Weili, Do, Young Rok, Lee, Mark Hong, Ng, Soo Chin, Lee, Won-Sik, Guo, Ye, Zhang, Huilai, Kang, Hye-Jin, Yun, Hwan Jung, Kim, Hyo Jung, Lung, Daryl Tan Chen, Kwak, Jae-Yong, Han, Jae Joon, Mun, Yeung-Chul, Oh, Sung Yong, Shim, Hyeok, Kwon, Jung Hye, Sohn, Byeong Seok, Park, Seong Kyu, Jo, Jae Cheol, Ko, Young Hyeh, Jun, Zhu, and Kim, Won Seog

Published
2021
Full Text
View/download PDF

46. Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia

Author

Yoon, Sang Eun, Song, Yuqin, Kim, Seok Jin, Yoon, Dok Hyun, Chen, Tsai-Yun, Koh, Youngil, Kang, Ka Won, Lee, Ho Sup, Tay, Kevin Kuang Wei, Lim, Soon Thye, Poon, Michele, Irawan, Cosphiadi, Zhao, Weili, Do, Young Rok, Lee, Mark Hong, Ng, Soo Chin, Lee, Won-Sik, Guo, Ye, Zhang, Huilai, Kang, Hye Jin, Yun, Hwan Jung, Kim, Hyo Jung, Lung, Daryl Tan Chen, Kwak, Jae-Yong, Han, Jae Joon, Mun, Yeung-Chul, Oh, Sung Yong, Shim, Hyeok, Kwon, Jung Hye, Sohn, Byeong Seok, Park, Seong Kyu, Jo, Jae-Cheol, Ko, Young Hyeh, Jun, Zhu, and Kim, Won Seog

Published
2021
Full Text
View/download PDF

48. Primary Nodal Epstein-Barr Virus-Positive T-Cell/NK-Cell Lymphoma: Real-World Experience.

Author

Choi, Dae-Ho, Yoon, Sang Eun, Cho, Junhun, Kim, Seok Jin, and Kim, Won Seog

Subjects
STEM cell transplantation, T-cell lymphoma, PROGRESSION-free survival, SURVIVAL rate, OVERALL survival
Abstract

Introduction: Primary nodal Epstein-Barr virus-positive T-cell/NK-cell lymphoma (PTCL-EBV) is a disease entity newly recognized in the World Health Organization's classification of hematolymphoid tumors, 5th edition (WHO-HAEMS5) and the International Consensus Classification of Mature Lymphoid Neoplasms (ICC). Previously, it was classified as a subtype within peripheral T-cell lymphoma, not otherwise specified, and was known to have a poor prognosis. However, the clinical features and treatment outcomes are not well known. Methods: This retrospective observational study was conducted on patients diagnosed with PTCL-EBV at Samsung Medical Center through a pathology review from 2000 to 2020. We analyzed the clinical data from 14 patients, immunohistochemistry, and survival outcomes including overall survival (OS) and progression-free survival (PFS) for each treatment regimen. PFS was defined as the time from the start of chemotherapy to the confirmation of disease progression on imaging, and hematopoietic stem-cell transplantation (HSCT) was considered a consolidation treatment. OS was defined as the time from diagnosis to the time of death. Results: 25% (1 out of 4) were beta-F1 positive, and 67% (4 out of 6) were T-cell receptor gamma (TCRγ) positive. T-cell intracellular antigen (TIA-1) and granzyme B exhibited positive results in all cases (3 out of 3), whereas the NK-cell marker CD56 was positive in only 11% of patients (1 out of 9). CD3 was observed in all of the patients (11 out of 11). The CD4 was 43% positive (3 out of 7). The CD8 was investigated in 8 patients, with 37.5% positive (3 out of 8). Hepatosplenomegaly was observed in 55% of patients (6 out of 11), and 70% (7 out of 10) of patients displayed B symptoms at the time of diagnosis. Patients who received CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or CVP (cyclophosphamide, vincristine, prednisolone) treatment had a median PFS of 2.2 months (95% CI: 1.9–2.5 months), and patients who received other treatments had a median PFS of 5.1 months (NA). The objective response rate (ORR) for ICE/dexa (ifosfamide, carboplatin, etoposide, dexamethasone) as the first- or second-line treatment was 100% (3 out of 3). But ORR of CHOP or CVP as the first-line treatment was 33.3% (3 out of 9). The median OS for the group that received HSCT (3 out of 11) after achieving a response was 34.6 months (95% CI: 0–74.6 months), and the median OS for the group that did not receive HSCT (8 out of 11) was 5.0 months (95% CI: 2.1–7.9 months) (p = 0.04). Conclusions: In conclusion, in the context of PTCL-EBV, despite a limited sample size, the ICE/Dexa regimen shows potential benefits in terms of ORR and PFS. Furthermore, the application of HSCT following the attainment of a complete response may prove advantageous. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Combination of rituximab and methotrexate followed by rituximab and cytarabine in elderly patients with primary central nervous system lymphoma.

Author

Yi, Jun Ho, Kim, Seok Jin, Yang, Deok‐Hwan, Do, Young Rok, Won, Jong Ho, Baek, Dongwon, Shin, Ho Jin, Kim, Dae Sik, Kim, Hyo Jung, Kang, Ka‐won, Bae, Sung Hwa, Kwon, Ji‐Hyun, Kwon, Jung Hye, Park, Byeong Bae, and Kim, Won Seog

Subjects
OLDER patients, CENTRAL nervous system, METHOTREXATE, OVERALL survival, RITUXIMAB
Abstract

Summary: The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II study to evaluate the efficacy and safety of rituximab plus high‐dose MTX followed by rituximab plus cytarabine in patients aged ≥60 years newly diagnosed with PCNSL. Patients received an induction treatment of high‐dose methotrexate plus rituximab followed by two cycles of a consolidation treatment of cytarabine plus rituximab. The primary end‐point was a 2‐year progression‐free survival (PFS) rate. A total of 35 patients were recruited, and their median age was 73 (range: 60–81). After induction treatment, the complete and partial responses (PRs) were 56% and 20% respectively. Twenty‐six patients proceeded to the consolidation treatment; the complete and PRs were 59% and 9% respectively. After a median follow‐up duration of 36.0 months, the 2‐year PFS rate was 58.7%. Treatment was generally well‐tolerated as only three patients were withdrawn from the study due to toxicity, and no treatment‐related mortality was reported. The 2‐year overall survival rate was 77.9%. The current study may suggest the feasibility of administering high‐dose MTX plus cytarabine in PCNSL patients aged ≥60 years and the potential role of additive rituximab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results